Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914710 | 0.98 | GAA (1.00) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL916128 | 0.97 | NPSR1 (1.00) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL915757 | 0.81 | HTT (0.68) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL4694133 | 0.80 | HTT (0.67) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL3637702 | 0.80 | HTT (0.67) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL6031412 | 0.79 | GAA (0.68) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL4691404 | 0.79 | HTT (0.65) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL2951788 | 0.78 | NPSR1 (0.68) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL14459794 | 0.78 | HTT (0.63) | HTTKMT2ACHEK1TSHRGAA | |
| SCHEMBL939440 | 0.78 | KDM4E (0.64) | HTTKMT2ACHEK1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352031-A1 | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-10-24 | — | — | US | disclosed |
| US-12006328-B2 | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto | EMORY UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10751320-B2 | Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders | LOTHERA, LLC | 2020-08-25 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9981981-B2 | Tricyclic proteasome activity enhancing compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981981-B2 | Tricyclic proteasome activity enhancing compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2595993-B1 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | HARVARD COLLEGE (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009109983-A1 | THIENO[2,3-D]-PYRIMIDINE-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | NATIONAL CHEMICAL LABORATORY (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008117269-A2 | HETEROTRI CYCIII C COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR HOLDING S.A. (LU) | 2008-10-02 | — | — | WO | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| US-6849638-B2 | 4-AMINO-5,6-SUBSTITUTED THIOPHENO [2,3-D] PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND THEIR USE IN THE TREATMENT OR PREVENTION OF PDE7B-MEDIATED DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2002002568-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | KNOLL GMBH (DE) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | HTT 4842/4885KMT2A 1082/4885CHEK1 45/4885 |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | HTT 3172/4885KMT2A 2584/4885CHEK1 89/4885 |
| US-12006328-B2 | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto | GRIN2A, GRIN3A, GRIN1 | HTT 498/4885KMT2A 369/4885CHEK1 806/4885 |
| US-10751320-B2 | Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders | NCSTN, CHLSN, CNTN1 | HTT 7/4885KMT2A 2826/4885CHEK1 3041/4885 |
| US-20240352031-A1 | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto | GRIN2A, GRIN3A, GRIN1 | HTT 498/4885KMT2A 369/4885CHEK1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.